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Abstract: Studies on unmet needs during the last decades have played a significant role in 
the development and dissemination of evidence-based community practices for persistent 
schizophrenia and other severe mental disorders. This review has thoroughly considered several 
blocks of unmet needs, which are frequently related to schizophrenic disorders. Those related to 
health have been the first block to be considered, in which authors have examined the frequent 
complications and comorbidities found in schizophrenia, such as substance abuse and dual 
diagnosis. A second block has been devoted to psychosocial and economic needs, especially 
within the field of recovery of the persistently mentally ill. Within this block, the effects of the 
current economic difficulties shown in recent literature have been considered as well. Because 
no patient is static, a third block has reviewed evolving needs according to the clinical stag-
ing model. The fourth block has been dedicated to integrated evidence-based interventions to 
improve the quality of life of persons with schizophrenia. Consideration of community care for 
those reluctant to maintain contact with mental health services has constituted the fifth block. 
Finally, authors have aggregated their own reflections regarding future trends. The number of 
psychosocial unmet needs is extensive. Vast research efforts will be needed to find appropriate 
ways to meet them, particularly regarding so-called existential needs, but many needs could 
be met only by applying existing evidence-based interventions. Reinforcing research on the 
implementation strategies and capacity building of professionals working in community settings 
might address this problem. The final aim should be based on the collaborative model of care, 
which rests on the performance of a case manager responsible for monitoring patient progress, 
providing assertive follow-up, teaching self-help strategies, and facilitating communication 
among the patient, family doctor, mental health specialist, and other specialists.
Keywords: schizophrenia, needs, unmet needs, severe mental disorders
Introduction
Since the middle of the last century, three successive approaches can be distinguished 
in the management of schizophrenia. In the 1960s, management was mainly focused 
on psychopathology, with little attention paid to contextual factors. Psychoanalysis, 
family therapy, rehabilitation, and the recently discovered neuroleptics were applied 
with more or less emphasis, depending on the theoretical affiliations of the clinicians. 
The needs of the patients and the methods of satisfying them were defined by the 
medical staff, and as a consequence, they were mainly of a clinical nature.
After deinstitutionalization, patients were faced with the difficulties of living in 
the community, and their psychiatric management had to take these difficulties into 
account. As mental health services increased in extension and diversity, management 





became more service-oriented. Facilitating access to housing, 
occupation, company, and social relationships was included 
in the management of schizophrenia, together with the previ-
ously identified clinical aspects.
In the last decades, the rising awareness of human 
rights and democratic sensibility in society at large has 
contributed to the empowerment of users of mental health 
services. Patients and carers both started to get involved in 
the identification of their individual needs. This resulted in 
the recognition of needs linked to human rights, such as the 
need for freedom and respect, and the so-called existential 
needs, such as the need for spirituality and the need to have 
a meaningful life.
Further refinement of the management of schizophrenia 
has been stimulated and supported by the development of 
instruments for the assessment of needs and the elaboration 
and diffusion of clinical practice guidelines (CPGs).
Management has become more specific under the influ-
ence of instruments developed for describing and quantify-
ing psychopathological symptoms and signs, particularly 
in clinical research, such as questionnaires, clinical rating 
scales, and diagnostic interviews. The routine use of these 
measures is thought to improve decision-making and patient 
care.1 Recently, there has been growing interest in including 
patients’ psychosocial performance and quality of life as 
essential parts of the aims for treatment, with a subsequent 
emergence of tools developed to measure them.
With the advent of community psychiatry, new tools to 
assess patients’ psychosocial needs were developed. The 
Camberwell Assessment of Need is a good example of a tool 
developed to comprehensively evaluate several aspects of an 
individual’s life and mental well-being. The views of staff 
members and service users are registered separately, allow-
ing differences of opinion to be identified and a management 
plan to be negotiated.2
The prominence gained by users and their relatives in 
health care has led to their participation in the elaboration 
of new instruments, such as the Maristan Scale of Needs.3 
This instrument is based on qualitative data obtained from 
users, carers, and professionals across several cultures and 
contains four factors: health needs, work and leisure needs, 
existential needs, and needs for support in daily life.3,4
In addition to their contribution to refining management 
and supporting decision-making, these instruments have 
helped to detect, define, and measure unmet needs and to 
identify new needs. Information about unmet needs may 
be obtained by directly asking the patient about them in the 
course of routine interviews; by making inferences from 
data, as well as from epidemiological surveys; or by using 
established needs assessment instruments.5
From a public health perspective, the unmet needs of 
persons with schizophrenia who have not made contact with 
health services are also a major problem. The treatment gap 
(TG) for schizophrenia across the world, including other 
nonaffective psychoses, has been estimated at 32.2% by the 
World Health Organization.6
CPGs gather recommendations, based on research evi-
dence, on how to manage schizophrenia. More than 20 CPGs 
from 18 countries have been published and are in use at the 
present time.7 Despite the fact that CPGs are widely known 
and contain viable and effective recommendations, actual 
implementation is often suboptimal. Discordance in CPG 
recommendations regarding psychosocial interventions8 
may not help reduce observed practice variations in this 
area, but even in the area of psychopharmacology, evidence 
 suggests that the management of schizophrenia is often poor.9 
Inadequate implementation of CPGs may be caused by scarce 
resources, poor management of the available resources, and 
the effects of stigma. Multiple strategies have been proposed 
to improve CPG implementation.10
In summary, the management of schizophrenia at present 
is not supported by a finished and coherent body of scientific 
evidence but has, rather, developed during the last 50 years 
as a complex process of interactions among research, pro-
fessional practice, service provision, user’s experience, and 
mental health advocacy, and it is still evolving.
Unmet health care needs: 
complications and comorbidities  
of schizophrenia
Despite considerable advances in the process of care, 
schizophrenia and its related mental disorders are quite often 
associated with negative health outcomes. Plausible deter-
minants include adverse effects of medication, drug abuse, 
smoking, inactivity, and disorganized patterns of nutrition 
and hygiene, which may facilitate the occurrence of seri-
ous comorbid medical problems such as obesity, metabolic 
syndrome, diabetes, and cardiovascular disorders, as well 
as chronic infective disorders. Substance abuse is the most 
common comorbidity among patients with schizophrenia and 
has a strong effect on the clinical picture (psychopathology), 
diagnosis, course of treatment, and prognosis.
Because of specific clinical characteristics (eg, delu-
sions, negative symptoms, neurocognitive dysfunction, and 
disorganization), schizophrenia may impair the patient’s 
capacity to identify symptoms of medical illness, report 





them to health professionals, and engage in treatment, in 
addition to complying with regular medical appointments 
plus prescribed medication.
Studies on the relationship between psychopathological 
symptoms in schizophrenia and quality of life have shown 
that negative symptoms and general psychopathology are 
the best predictors of quality of life in these patients.11 In 
contrast, the severity of negative symptoms and cognitive 
deficits are the best predictors of the objective dimension of 
quality of life.12 In addition, a higher severity of symptoms 
is related with a lower quality of life.13
Somatic conditions
The literature shows that there is a significant association 
between schizophrenia and several somatic disorders such 
as nutritional/metabolic disorders, cardiovascular conditions, 
and sexual dysfunctions, among others. Obesity, diabetes, 
and smoking are two times more frequently seen among 
patients with Severe Mental Disorder (SMD) than in the 
general population.14 These conditions may compromise 
medication compliance and the quality of life of patients with 
schizophrenia. Furthermore, life expectancy in schizophrenia 
is reduced, with an excess mortality that is two times higher 
than that in the general population,15,16 with cardiovascular 
diseases responsible for 50% of the excess mortality associ-
ated with schizophrenia diagnosis.17–22
Despite the contribution of several factors, the most 
important determinants of the poor somatic health of this 
population seem to be lifestyle-modifiable risk factors (smok-
ing, alcohol, drugs, and lack of exercise), adverse effects of 
prescribed psychotropic medication, and poor access to good-
quality mental health services. In fact, although psychiatrists 
are conscious of potential somatic problems in persons with 
schizophrenia, physical health assessment and management 
have been reported frequently as being scarce.23 This poor 
recognition of somatic conditions might be a result of reduced 
physical assessment skills, particularly after a long time of 
exclusive psychiatric practice.
Metabolic and nutritional problems are among the most 
reported findings not only in schizophrenia but also in 
other SMD. In schizophrenia, an increased likelihood risk 
for overweight, obesity, and abdominal obesity is present 
even in recently diagnosed and nonmedicated patients.24 
Psychotropic medication is strongly associated with sexual 
dysfunctions25 and obesity,26 particularly in patients with 
significant negative symptoms, reduced social interaction, 
and disorganized behavior. Both conditions limit patients’ 
everyday interpersonal relationships and frequently become 
their reason to reject medication. Although most antipsy-
chotics may cause overweight, the risk seems greater for 
clozapine and olanzapine and smaller for aripiprazole and 
ziprasidone, with quetiapine and risperidone showing an 
intermediate risk profile.27,28 Mood stabilizers, such as lithium 
and valproate, and several antidepressants, particularly the 
tricyclic antidepressants, are also associated with a significant 
risk for obesity in schizophrenic patients.29
Patients with schizophrenia present with an excessive 
risk for metabolic syndrome (MS).30,31 Obesity and insulin 
resistance are core components of MS, together with hyper-
tension, elevated triglycerides, and established determinants 
of diabetes. MS is strongly associated with increased mortal-
ity because of cardiovascular risk and might be present in 
almost half of the psychotic patients even 20 years after their 
first psychotic episode.32 Patients prescribed with second-
generation antipsychotics show a higher incidence rate of MS 
than patients treated with first-generation antipsychotics.33 
Despite this evidence, metabolic screening and monitoring 
are still limited, even in developed countries with effective 
health systems.34
Regarding type 2 diabetes, the prevalence of this illness 
in patients with schizophrenia is five times higher compared 
with in the general population, with a significant association 
with clozapine and olanzapine. Moreover, the TG of diabetes 
among schizophrenic patients remains quite high, reaching 
nontreatment rates around 40% in large-scale multicentric 
studies.35,36 The elevated prevalence of these metabolic 
problems may explain why the death rate from cardiovas-
cular disorders in schizophrenic patients has not declined in 
recent years in developed countries, as it has in the general 
population, and stands as the first cause of mortality among 
patients with SMD.18,37 Patients with schizophrenia and other 
SMD are at greater risk of coronary heart diseases,19 stroke,38 
ventricular arrhythmias,39 and sudden death.40 Given that the 
excess of cardiovascular mortality is, at least partially, a result 
of modifiable risk factors (lack of exercise, obesity,  smoking), 
there is a need to improve the access of schizophrenic patients 
to primary care facilities, where these issues can be evaluated 
and monitored first-hand.
In addition to metabolic and cardiovascular diseases, 
particular attention should also be given to other condi-
tions frequently associated with poor physical outcomes in 
schizophrenia. For instance, in places where institutional-
ization remains the principal model of care, infections such 
as pneumonia and tuberculosis are still more prevalent in 
the institutionalized population than in noninstitutionalized 
populations.41,42 Heavy smoking, a strong risk factor for 





respiratory disorders, is much more common among psy-
chiatric patients diagnosed with schizophrenia, particularly 
in long-term institutionalized patients, than in the general 
population (80% versus 20% in the adult population).43 
Restoration of nicotine function, amelioration of unwanted 
dopamine blockade adverse effects, and improvement of 
cognitive and negative symptoms have been reported as 
possible causes for this finding, according to neurobiological 
research findings.43
In addition, considerable risk for the occurrence of dis-
eases caused by viral infections, such as HIV (estimated to 
be 4%–23%),26 hepatitis B, and hepatitis C, which is often 
related to intravenous drug abuse and unprotected sexual 
activity, has been systematically reported in schizophrenic 
patients.44
Although schizophrenia has been associated in several 
well-conducted studies with a decreased risk for cancer even 
after controlling for smoking, there are yet some conflicting 
results, and the subject is not closed.45 Possible sources of 
bias are the decreased access of psychotic patients to general 
medical services, the lower rate of autopsies among those 
patients, and the poor quality of some mental health case 
registers.46 More important from an organizational perspec-
tive, a large-scale study conducted in Australia showed that 
despite the lower incidence of neoplasm in schizophrenia 
patients, mortality resulting from cancer was increased (39% 
higher in men and 24% higher in women; range, 17%–32%) 
when compared with the general population, suggesting 
once again an unmet need in the access of those patients to 
medical services.47
Hyperprolactinemia, a common adverse effect of first-
generation antipsychotics, has also been associated with 
breast cancer, osteoporosis, and hypogonadism, but the 
results are contradictory.48
Substance abuse and dual diagnosis
According to recent data, only 12.4% of American adults 
with dual diagnosis receive both mental health and substance 
abuse treatment.49 Comorbidity may be a result of several 
factors, probably in association. Mental disorders may predis-
pose to the onset of substance use disorders in situations such 
as disinhibition, mood swings, overwhelming anxiety, and 
the adverse effects of medication. In contrast, substance use 
disorders may lead to the onset and maintenance of mental 
disorders through biological mechanisms such as heavy can-
nabis use during adolescence or comorbid panic and cocaine 
abuse resulting from brain kindling. Finally, common genetic 
and environmental causes should not be disregarded, as they 
may share similar physiopathological processes leading to 
an increased lifetime risk for comorbidity.
Epidemiological estimates of dual diagnosis may change 
with the definition criteria, the ability of mental health profes-
sionals to detect the problem, and the tools used to measure 
the disorders. Taking into account these methodological 
limitations, prevalence rates are still very substantial.
In the National Comorbidity Survey, 51.4% of respon-
dents with a lifetime diagnosis of substance abuse disorder 
(including alcohol and drugs) also met criteria for at least 
another lifetime mental health disorder, with an odds ratio 
of 2.4.50 Other studies conducted in different places and set-
tings also show high prevalence rates of comorbidity, rang-
ing between 37% and 53%, both in community surveys and 
clinical samples.51 Conversely, up to 66% of patients with 
schizophrenia meet criteria for at least a single substance-
related disorder in their lifetime.51
There is growing evidence that patients with a dual 
diagnosis do not respond well to conventional psychiatric 
treatment, creating demand for a new approach from a dif-
ferent perspective.52 In fact, particular attention has to be 
given to the characteristically greater clinical severity, the 
greater exposure to environmental risk factors, the potential 
abuse of currently used pharmacological agents, and the lack 
of specific training of mental health professionals in deal-
ing with this population. The shortage of trained clinicians 
as well as the widespread scarcity of specialized facilities 
offering integrated programs, even in developed countries, 
is a strong determinant of the high level of unmet needs for 
care in this area.53
Other psychiatric comorbidities
Psychiatric comorbidities are much more common among 
patients with schizophrenia than what would be expected by 
chance alone.54 Anxiety and depressive symptoms are seen 
quite frequently during the course of illness, with an estimated 
prevalence of 15% for panic disorder, 29% for posttraumatic 
stress disorder, and 23% for obsessive-compulsive disorder. 
Surveys estimated that depression occurs in 50% of patients 
with schizophrenia, both during and after the emergence of 
florid psychotic symptoms.55 In addition, depression reduces 
quality of life in schizophrenic patients.56,57
A recent systematic review of suicide in schizophrenia58 
reported that lifetime risk of suicide was approximately 5%. 
Risk factors included young age, being male, being edu-
cated, prior suicide attempts, depressive symptoms, active 
hallucinations and delusions, substance abuse, and the 
presence of insight. According to this review, delivery of 





effective treatment was the only reliable protective factor 
for suicide.
As we have shown, there is scientific evidence that patients 
with schizophrenia require comprehensive care focused on 
both their mental and physical needs.22 However, these patients 
are not regularly examined to assess their physical condition 
and the possible organic effects of pharmacological treat-
ments. It is only recently that specific assessment protocols 
have been established for the follow-up of obesity, sedentary 
lifestyle, and life habits in these patients. In addition, patients 
with schizophrenia have more difficulties getting access to pri-
mary care59 and are less likely treated for physical problems.60 
In the absence of scientific evidence for specific interventions, 
the use of CPGs is recommended to mitigate cardiovascular 
risk in patients with schizophrenia.61
Unmet psychosocial  
and economic needs
Patients with schizophrenia usually present with difficulties 
in diverse areas of daily life: they are predominantly unem-
ployed, single, and have a low educational level.62–64 They 
have also difficulties with housing, as the Team Assessment 
Psychiatric Services (TAPS) project described65 and current 
literature emphasizes,66 and their income depends on commu-
nity aids.67 A high proportion of patients with schizophrenia 
have little or no social contact or friends, present with a high 
risk of isolation, and have difficulties getting involved in 
leisure activities.67
In general, unmet needs differ depending on the socio-
cultural environment. Results from the European Psy-
chiatric Services: Inputs Linked to Outcomes and Needs 
(EPSILON) study comparing users’ needs in five European 
cities showed that needs diverge in different contexts and 
that more unmet needs were found in big urban areas,68 
where poverty, unemployment, and other social problems 
are more severe.69 Psychosocial needs were reported by users 
as the most unmet and included daily activities, company, 
and intimate relationships.70 Similar findings were found in 
studies with users from Nordic countries, where psychosocial 
needs were also the most unmet, particularly those related 
to social relationships,71 which were also the most related to 
patients’ quality-of-life perception.72 Social contact is one of 
the main domains related to quality of life and is the area in 
which schizophrenia patients claim the most dissatisfaction. 
Moreover, frequency of contact with relatives or friends has 
been shown to be a predictor of quality of life.73 Inversely, 
stigmatization and social exclusion may negatively affect 
perceived quality of life in patients with schizophrenia.74 
It has been proven that patients presenting with a higher 
quality of life show a better perception of family function-
ing, which confirms the importance of families as social and 
emotional support networks and agents in meeting individu-
als’ needs.75 In a Spanish study, users identified as unmet 
those needs related to health and social services provision, 
including psychotic symptoms, house upkeep, food, and 
information.76 These results were similar to those presented in 
a study comparing patients’ needs in five European and Latin 
American countries, where Argentinean patients identified 
more needs related to health care, probably because of the 
fragmentation of their health system and their dependence on 
psychiatric hospitals.3 In India, a study found that two-thirds 
of patients’ needs were unmet, the most important of which 
were psychotic symptoms, psychological stress, information, 
and money.77
The organization and provision of care in health systems, 
together with life conditions in the cities, undoubtedly influ-
ence needs satisfaction. When these systems are less wealthy, 
instrumental and economic aspects become more important; 
when these needs are satisfied, patients give more weight to 
social relationships.
Unmet needs can be classified in different levels (eg, 
community or health services) and from different perspec-
tives (eg, users, families, and health teams). Mojtabai and 
colleages78 pointed out that according to epidemiological 
studies in the United States, at least 40% of patients with 
schizophrenia continue living in the community without any 
type of treatment for long periods of time, even if they pres-
ent with significant symptoms. The main barrier for access 
to services is stigma associated with mental illness. Thus, 
negative perceptions about mental illness in the users are 
related to a higher number of unmet needs and to negative 
attitudes toward medication.79 In contrast, there is another 
group of patients that uses health services but presents with 
scarce adherence to treatment. In both groups, unmet needs 
are estimated from the comparison between recommended 
treatments and service use patterns.78
Along these lines, it has been shown that users present 
with different needs, depending on the type of intervention 
they are receiving. Cleary and colleagues80 found that patients 
with SMD, both in inpatient and community settings, shared 
the same unmet needs (daily activities, company, and intimate 
relationships) but that these needs were greater among institu-
tionalized patients. In contrast, it has been shown that patients 
using long-term services require promotion of independence, 
stability in housing, stability in social networks, consistency 
of care, and addressing the theme of loss.81 Apparently, the 





unmet needs of users attending community and rehabilita-
tion services tend to increase and change over time, with 
psychosocial needs perceived as the most important.82 In a 
study comparing the needs of users under rehabilitation pro-
grams in two points in time, more unmet housing and money 
needs were found in the present compared with in data from 
1998.83 These results lead to the hypothesis that needs are 
also sensitive to sociocultural changes, which could limit its 
use in services comparing assessment.84
Most studies agree that users, relatives, and health staff 
differ on their perceived unmet needs.85,86 A recent study 
found that health personnel reported a greater number of 
unmet needs than users.87 For the latter, unmet needs are 
mainly focused in the areas of social, personal, and intimate 
relationships.
In contrast, unmet needs also depend on the vital cycle 
stage and, thus, on the illness stage the patients are in. In older 
adults, most unmet needs are focused in the psychosocial and 
general health care areas,88 and the psychosocial and social 
areas are less covered than the environmental and physical 
areas.89 However, studies on first-episode psychosis are 
scarce. In one of these few studies, young people reported 
that 20% of their needs were unmet.90
These data are alarming, as most social impairment in 
schizophrenia occurs at the beginning of the illness, between 
the second and the fifth year after onset.91 This is why 
treatment of first episodes emphasizes not only symptoms 
reduction but also prevention of social decline. In the only lon-
gitudinal study published so far on the needs of first- episode 
schizophrenia patients, results showed that daily activities, 
psychotic symptoms, psychological stress, and social integra-
tion were most frequently reported as unmet needs. In the 
follow-up, second-generation medication showed no effect 
on the course of unmet needs.92 Antipsychotic treatment alone 
was not sufficient to account for the psychosocial needs of 
patients. In spite of that, interventions are still focused on 
symptoms management, instead of on rehabilitation or on 
improving social and occupational functioning.78 In contrast, 
unmet needs have been associated with risk behaviors such 
as aggression93 and can predict suicide when unmet need is 
related to interpersonal contact.94
It is important to bear in mind that, conversely, quality 
of life is also influenced by sociodemographic factors such 
as unemployment,75,95 sex, or age.73 It also has been found 
that male and older patients present with a poorer quality 
of life. In addition, the gap in unemployment rates between 
individuals with and those without mental health problems 
is significantly widened by financial crisis.96 Recent evidence 
supports that mental health recovery services should include 
programs that address employment issues.97
The clinical staging model
In the last 15 years, a new diagnostic approach has been 
developed in an attempt to overcome the limitations of the 
current diagnostic system (lack of validity and therapeutic 
utility): the clinical staging model.98 According to this model, 
studying the course, extension, and pattern of illness over 
time provides a more useful diagnostic system for both 
clinical practice and research. This model is based on the 
idea of providing the earliest possible effective intervention 
that could prevent progression to more advanced stages, or 
even promote regression to an earlier stage, including total 
remission.98 The identification of early clinical symptoms 
is the focus of this model, which makes it especially useful 
for adolescents and young adults – those at the age when 
onset of psychotic disorders usually occurs. The rationale for 
this focus on early detection and intervention is the robust 
association between longer duration of untreated psychosis 
and poorer response to treatment both on a short- and long-
term basis.99,100
According to the clinical staging model, psychotic dis-
orders evolve through three initial stages: the ultra-high risk 
(UHR) stage, the first-episode psychosis (FEP) stage, and 
the critical period of early psychosis.
Criteria for the identification of individuals at high risk 
(UHR) include attenuated positive psychotic symptoms, 
brief self-limited psychotic symptoms, and family history 
of psychotic disorder.98 Using these criteria, around 40% of 
individuals identified as UHR presented with FEP within a 
1-year follow-up, even after receiving needs-based psycho-
social interventions.98,101–105 Studies on different interven-
tion approaches in the UHR stage of psychosis have come 
to the conclusion that first-line treatments in UHR patients 
must be mild, including psychosocial interventions such as 
cognitive-behavioral therapy (CBT) or supportive therapy, 
or supplementation with eicosapentaenoic acid. If necessary, 
pharmacological approaches could also be employed, with 
aripiprazole as the best candidate.98
Once a full psychotic episode is detected, the patient 
enters the FEP stage. In this stage, the main objective is to 
obtain the patient’s engagement in pharmacological and psy-
chosocial treatments. Interventions in this stage are broadly 
described in the International Clinical Practice Guidelines for 
Early Psychosis,106 published in 2005, and were supported by 
the European First Episode Schizophrenia Trial (EUFEST) 
study107, favoring second-generation antipsychotics as 





first-line therapy in FEP, given their better tolerability. The 
inability of medications to produce significant improvements 
in patients’ functioning has produced an increased interest in 
psychosocial interventions such as the need to enhance social 
recovery,108 especially in the educational and vocational 
field.109,110 In addition, cognitive remediation is one of the 
focuses in this stage.111,112 In summary, in this stage, both effec-
tive psychosocial intervention and well-managed medication 
are fundamental to avoiding progression of the illness.
The critical period in early psychosis is defined as the first 
2–5 years after the diagnosis of a psychotic disorder. This is a 
very important stage, as it coincides with major developmen-
tal challenges such as forming a stable identity, peer network, 
vocational training, and intimate relationships.98 Treatment in 
this stage is aimed at minimizing the risk for relapse and the 
disability associated with the disorder, as well as maximiz-
ing social and functional recovery. Moreover, interventions 
should also be focused on maximizing the chances of treat-
ment engagement, continuity of care, appropriate lifestyle, 
family support, and vocational recovery and progress. This 
can be achieved through patients’ engagement in combined 
pharmacological and psychosocial interventions. However, 
here we find a huge TG between what is needed and what is 
provided, even in most developed countries113,114 (see section 
on Community Care for those reluctant to maintain contact 
with mental health service).
Nowadays, mental health services, particularly those 
oriented toward rehabilitation, promote a recovery view of 
service. Recovery is an individual process implicating the 
development of a new meaning and purpose in life beyond 
the psychiatric illness.115 Needs assessment permits going 
further than recovery from an individual point of view, as it 
shows where intervention is more important not only from 
the patient’s but also from the social environment’s point of 
view.87 As a consequence, needs assessment can be consid-
ered an articulating tool between the patient and the social 
environment beyond the illness itself.
Integrated evidence-based 
interventions to improve the quality 
of life of persons with schizophrenia
Quality of life has been considered as a unified concept 
to assess the effect of illness on daily life of people with 
 schizophrenia.116 The main dimensions to assess this 
construct include psychopathological state, physical health, 
socio demographic factors, level of functioning for daily life 
activities, and social relationships, understood as interpersonal 
contacts and involvement in social and leisure activities.117–120 
There is a general accord in considering that quality of life 
should reflect a person’s well-being, both at the objective and 
subjective levels, and that it refers to general satisfaction with 
life. The literature on this issue has shown that patients with 
schizophrenia present with a lower quality of life compared 
with healthy people in the community.116
Although the treatment of patients with schizophrenia 
has been traditionally focused on symptoms, given that they 
are associated with hospitalization episodes, it is nowadays 
considered that this treatment must be more comprehensive 
and must allow integration of patients into their community. 
This is why quality of life has been considered to be a main 
target in the treatment of these patients.95
Although it is obvious that drugs alone are not enough for 
facing schizophrenia, most schizophrenic patients will need 
to be treated with antipsychotics. The sooner the patient is 
treated with antipsychotics after the onset of the disease, the 
better overall outcome. It is a severe risk for the patient if this 
worldwide-accepted axiom is forgotten and antipsychotics 
also become an unmet need.
Several evidence-based pharmacological and psycho-
social interventions to alleviate symptoms and improve 
functioning and quality of life of persons with schizophrenia 
are also available. Some of these interventions have been 
put together in packs of integrated care, such as the Optimal 
Treatment Project121 and the Patient Outcomes Research Team 
(PORT) report,122 and their feasibility and cost- effectiveness 
have been proved in naturalistic studies.
A recent systematic review and meta-analysis comparing 
antipsychotic drugs with placebo on relapse prevention in 
schizophrenia concluded that sustained antipsychotic treat-
ment of patients diagnosed with schizophrenia lowers their 
risk of relapse, especially when depot preparations were used 
and independent of whether the antipsychotic belonged to the 
classic or the new generation of drugs. Authors recommend 
further studies focused on outcomes of social participation 
and related to long-term mobility and mortality rates induced 
by these treatments.123
Another extensive (data for 43,049 participants) and 
recent meta-analysis shows a comparison of the efficacy 
and tolerability of 15 antipsychotic molecules. According 
to the results, all drugs were significantly more effective 
than placebo, and the different molecules differ clearly in 
adverse effects and prove “small but robust” differences 
regarding their efficacy. Moreover, the authors question the 
accepted hierarchy of first-generation and second-generation 
antipsychotics, finally recommending the use of the drug best 
adapted to the needs of the individual patients.124 With regard 





to this issue, in routine clinical practice it is advisable to 
follow the findings and recommendations of the thoroughly 
detailed PORT study on schizophrenia.122
Falloon and colleagues conducted a multisite, worldwide 
(.80 centers), naturalistic study that should also be com-
mented on. The authors designed an “Optimal Treatment” 
package including only evidence-based strategies, with the 
main components being minimally effective antipsychotic 
drug strategies targeted to change symptom profiles, educa-
tion of patients and informal carers in stress management 
strategies, assertive case management, goal-oriented social 
and occupational skills training, and specific pharmacologi-
cal and/or psychological strategies for residual or emerging 
symptoms. The authors used a nonrandomized sample and 
did not apply the common exclusion criteria (comorbidity, 
dual diagnosis, etc), so the sample represented only typical 
clinical cases. According to their results, the combination 
of pharmacological and psychosocial strategies that had 
previously proven efficacious in controlled trials can be 
applied in routine practice without additional resources. The 
authors maintain that integrated optimal pharmacotherapy 
and psychosocial treatment programs may play a major role 
in expediting recovery from psychotic disorders and also 
are cost-effective.121
A very recent contribution by Mueser and colleagues 
offers additional evidence and claims for the clinical integra-
tion of empirically supported psychosocial interventions for 
schizophrenia.125
Respect for human rights  
of the mentally ill
Since the early 1990s, most international bodies have shown 
an increasing interest in the dignity of, the empowerment 
of, and respect for the mentally ill.126,127 Undoubtedly, this 
is a result of the “lobby-like” action of growing user move-
ments, but certainly it is also a result of the new, predominant 
fieldwork of therapists: the community. Users and profes-
sionals were becoming aware that they also have to face 
new challenges, including stigma and social needs, among 
many others.
Also in the 1990s, the World Psychiatric Association 
started an ambitious Global Program to Reduce Stigma, 
known as Open the Doors.128 However, the results did not 
support the utility of an antistigma campaign with a broad 
approach but, rather, suggested a more specific focus, such 
as perceived dangerousness.129 The profound association in 
people’s imagination between dangerousness and mental 
disorder, especially schizophrenia, constitutes a strong 
reality reinforced by media, and the fight against that con-
nection should not be eliminated from any plan for mental 
health action.
One of the most common risks of a person suffering 
from schizophrenia under community care is being admit-
ted to a hospital because of his or her mental conditions. 
The mere fact of hospitalization is a risk in itself because 
of the added stigma, plus the frequent suffering of lowering 
self-esteem and loss of dignity perception when coerced 
into involuntary treatment. Moreover, mostly if admit-
ted compulsory, patients may also suffer other means of 
coercion to restrain their movements, such as mechanical 
constraint, isolation, or administration of nontherapeutic 
aimed drugs.
All this was extensively considered in the European 
Evaluation of Coercion in Psychiatry and Harmonization of 
Best Clinical Practice (EUNOMIA) study, supported by the 
European Commission in 12 countries.130–132 For the purposes 
of this review, the EUNOMIA findings can be summarized 
as follows:
1. There is a great heterogeneity on legislation across Europe 
regarding required conditions and procedures for com-
pulsory admission.131
2. In most countries, the conditions and procedures for 
applying other coercive means were not regulated.131
3. The mere voluntary hospitalization is not a harmless deci-
sion to the patient. Patients who feel coerced, even those 
who have been voluntarily admitted, may have a poorer 
prognosis than those involuntary admitted legally.133
4. Future studies should identify the factors in legislation 
and clinical practice, including important staff–patient 
interactions, that could lead to a more constructive coop-
eration of all parties involved.132
We could add that when some users were asked in focus 
groups (not published), none of the coercive measures were 
naive to the patients, and in some cases patients felt them 
as an attack on their dignity. This statement certainly needs 
more research, using an appropriate qualitative method if 
possible.
Restoring users’ dignity and self-esteem through their 
progressive empowerment and autonomy should be part of 
any recovery program. Quite a few of the most recent docu-
ments of the international bodies and multinational agencies 
support this and offer similar recommendations toward the 
same aim.130,134,135 However, the need for a better coordination 
of the different strategies and plans of action launched by 





these international institutions to guarantee the commitment 
of their member countries is noticeable.
Community care for those reluctant 
to maintain contact with mental 
health service
For a long time it has been known that there are patients 
who show unmet needs of service contact or unmet needs 
of psychosocial contact and of pharmacological treatment. 
A worldwide figure of unmet needs or TG for SMD was 
32%, according to a World Health Organization report.6 In 
20014, another World Health Organization European study136 
showed that the TG of SMD living in the community ranged 
between 35.5% and 50.3%, including in the most developed 
countries.
Lack of insight, past experiences, and prejudices against 
health services, among other reasons, make this group of 
people reluctant to maintain therapeutic links. They live in 
the community, and without adequate treatment, they are at 
risk of progressive health deterioration, forced reinstitution-
alization, or even imprisonment.137,138
The first of the two previously mentioned World Health 
Organization reports6 proposed ten recommendations to 
address the TG:
 1.  Mental health treatment should be accessible in pri-
mary care.
 2.  Psychotropic drugs need to be readily available.
 3.  Care should be shifted away from institutions and toward 
community facilities.
 4.  The public should be educated about mental health.
 5.  Families, communities, and consumers should be 
involved in advocacy, policy-making, and forming 
self-help groups.
 6.  National mental health programs should be established.
 7.  The training of mental health professionals should be 
increased and improved.
 8.  Links with other governmental and nongovernmental 
institutions should be increased.
 9.  Mental health systems should be monitored, using qual-
ity indicators.
10. More support should be provided for research.
More recently, a systematic World Psychiatric Associa-
tion survey of leaders of psychiatry was completed in almost 
60 countries, examining strategies to reduce the TG. The 
authors concluded that “scaling up of mental health services 
can only be achieved effectively if three elements are in place: 
task shifting to non-specialist providers; an increase in the 
specialist mental health resources to provide effective and 
sustained supervision and support; and a decentralization of 
those specialized mental health resources.”139
Mental health services policy makers have been con-
cerned about TG over the last decades, and many attempts 
have been made to solve it. Case management, intensive case 
management, assertive community treatment, and assertive 
outreach are or have been the most common names used to 
refer to successive models of community care specifically 
oriented to satisfy the unmet needs of the SMD.
It has been long known that assertive outreach and 
intensive case management can reduce hospitalizations of 
patients who are frequent users of inpatient care and can 
reduce overall mental health care costs. In addition, greater 
fidelity to the models produced better outcomes.140,141 This 
has also been validated in rural areas.142
SMD is very frequently found in the excluded home-
less population, making it more difficult to engage them in 
services care. It is then that assertive community treatment 
offers significant advantages in reducing homelessness and 
symptom severity in homeless people with SMD.143 The best 
outcomes for housing stability were found for programs that 
combined housing and support.144
These models of intensive care outreach services can 
have significant benefits in terms of patient outcomes and 
service use. Moreover, the implications of specific nursing 
programs provide a useful framework for evaluating the 
effect of these services.145
A recent Cochrane review found that intensive models 
of community care were more effective for several relevant 
outcomes of people with SMD. These not only reduced hospi-
talization and increased adherence to care but also improved 
social functioning, although the effect on psychopathology 
was not so clear.146
The effectiveness comparison of numerous attempts of 
available community models would be beyond the scope of 
the present revision. In summary, though, we could say there 
is a general accord on four basic criteria: the outreach team 
should be mobile instead of based at a mental health center; 
the team should have its own, full responsibility for care of 
a given bunch of clients; the caseload/staff member ratio 
should remain low; and the care at the client home should 
be part of the team routine.
Very recently, a Cochrane Systematic Review considered 
a new movement aimed at increasing the adherence of those 
patients with SMD who are reluctant to seek care. The review 
compared past or present users of mental health centers that 





were providing care versus professionals enrolled in case 
management. There were no significant differences between 
the two groups in clinical psychopathology, satisfaction, 
adherence to care, or withdrawing from the study, among 
other variables. Those receiving care from past or present 
users of mental health services used crisis and emergency 
services slightly less frequently than those receiving care 
from professional staff. Regarding care procedure, it was 
found that past or present users spent more face-to-face time 
with patients. The author invites others to further research 
this matter, reinforcing the methodological approach and 
changing the location in diverse settings, including low- and 
middle-income countries.147
Reflections regarding future trends
The number of psychosocial unmet needs is extensive. Vast 
research efforts will be needed to find appropriate ways to 
meet them, particularly regarding the so-called existential 
needs, but many could be met only by applying existing 
evidence-based interventions. Despite the general awareness 
of protocols, algorithms, and clinical practice guidelines, 
research findings are slow to reach into the daily manage-
ment of schizophrenia, and many useful and cost-effective 
techniques are ignored in practice.148 Reinforcing research 
on implementation strategies and the capacity-building of 
professionals working in community settings might help 
address this problem.
Regarding unmet health needs, evidence-based organi-
zational techniques for the management of chronic disorders 
could be applied extensively to severe mental disorders.149,150 
The Collaborative Model of Care may facilitate early detec-
tion and therapy of somatic disorders and improve treatment 
compliance in people with schizophrenia. This model of care 
rests on the performance of a case manager responsible for 
monitoring patient progress, providing assertive follow-up, 
teaching self-help strategies, and facilitating communication 
between the patient, the family doctor, the mental health 
specialist, and other specialists.
There are also unmet needs brought about by the psychi-
atric interventions themselves. Antipsychotic medications, 
while improving positive symptoms, may cause a variety of 
adverse effects that seriously interfere with quality of life. 
Use of low dosages, and even discontinuation of these medi-
cations in judiciously selected cases, will help to alleviate this 
problem as well as improve long-term functioning.151
Serious damage to quality of life may also come from some 
psychosocial interventions. The use of coercive procedures 
such as compulsory admission, community orders, or simple 
leverage, whether clinically justified or not, can be extremely 
detrimental to the quality of life. What is more, authoritar-
ian and stigmatizing attitudes of mental health professionals 
frequently act as a barrier for the identification of a patient’s 
preferences and needs. The participation of users and relatives 
in the planning and evaluation of mental health services and 
the growing collaboration between users, families, and mental 
health workers are key factors in bringing about the necessary 
change in these attitudes and behaviors. The incorporation of 
users in providing formal care within statutory mental health 
services is another example of this collaboration.147
One major advance in approaching the management of 
schizophrenia comes from conceiving it as a neurodevelop-
mental disorder that progresses in identifiable stages. Each 
developmental stage, modulated by sex and the phases of 
the vital cycle, is associated with different medical and psy-
chosocial needs, and hence requires different and specific 
interventions.152,153 In this context, management interests are 
presently being displaced from cognitive impairment and 
negative symptoms during the chronic phase to the early 
stages of development.
Another issue concerns social policy and the availability 
of community facilities to cover basic social needs. Quality 
of life is associated with employment, income, and housing 
stability. Unemployment, poverty, and housing instability are 
high among people with mental health problems, and even 
more so in times of economic recession.96 Social policies 
designed to cover these basic needs are a must if we want to 
avoid institutionalization and maintain the quality of life of 
people with schizophrenia. Along these lines, the preserva-
tion of the welfare state is critical. During the last decade, 
coinciding with the economic crisis and as a consequence 
of a tide of privatizations driven by neoliberal ideologies, 
some public health services in Europe are being dismantled. 
Advocacy for protecting the basic rights of persons with SMD 
is now more necessary than ever.
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